{
    "medicine_id": "cd9192baf3c2762916deef2f6d993097ed82609c",
    "platform_id": "DB04862",
    "metadata": {
        "name": "Bystolic 5 mg 1 Tablet",
        "composition": "5 mg 1 Merimepodib",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of hepatitis C virus HCV infection",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Merimepodib an oral drug contains a novel inhibitor of inosine monophosphate dehydrogenase IMPDH an enzyme responsible for stimulating the production of lymphocytes Merimepodib has the potential to exert direct antiviral activity as well as affect the immune response by acting on lymphocyte migration and proliferation Consequently merimepodib may be an effective treatment for hepatitis C virus HCV infection as the disease involves both viral proliferation and liver inflammation",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}